Activation of mutated EGFR and downstream intermediates—including RAF/MAPK, and PI3K/AKT/mTOR—eventually leads to increased proliferation and migration in NSCLC [5,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.